“Many psychologists believe that Impostor Syndrome is most common in high-achieving women and those who feel underrepresented or different from their colleagues such as people of color, the LGBTQ community, etc.”
—Robert Glazer, Forbes
"U.S. startups with all-women teams received 1.9% (or around $4.5 billion) out of the $238.3 billion in venture capital allocated, according to @PitchBook data- a notable drop from the 2.4% all-women teams raised in 2021."
This needs to change, now.
https://t.co/BaLTfDH5dq
“Don't worry about people stealing your ideas. If your ideas are any good, you'll have to ram them down people's throats.”
— Howard Aiken
via the 5-Bullet Friday newsletter (https://t.co/ENl5Mat9KP) from @tferriss
For #WomensHistoryMonth, we're celebrating outstanding scientists in the biotech industry. We salute Sarah Diermeier, founder and chief scientific officer of Amaroq Therapeutics, which is focused on developing a new class of therapeutics that target long non-coding RNAs in cancer
As another recent addition to the team, we are welcoming @KLucere!
Kat comes with a deep tech background (cancer research and neurobiology) in both US and NZ science ecosystems. She is now doing a stellar job supporting our BD efforts.
We are so excited to have you Kat!
We have some exciting job opportunities coming up🤩
If you are keen to develop the next generation of RNA therapeutics for oncology, please get in touch!
In our first lab gathering post lockdown today we celebrated the birthdays of PhD students @KLucere and Brandon Wright.
Great to be back and have fun with the team again!
Meet the team: part 2
Our R&D team also includes three amazingly talented PhD students. Together we are exploring long non-coding RNAs as new therapeutic targets in cancer.
Front row l->r:
@MMROMalley, Kaitlyn Tippett and @KLucere
Another new Review from our lab:
We discuss currently available functional screening methods to identify lncRNAs with therapeutic potential in cancer.
Awesome effort by @MeganOM31719615 and @KLucere@OtagoBiochemist
https://t.co/6D9aJlg5qc